Iovance Q1 revenue $71M (+45% YoY); guides FY26 $350-370M; endometrial cancer 40% cORR

IOVANCE BIOTHERAPEUTICS, INC.

2026-Q1 EPS reported -$0.19 revenue$71,430,000

Total product revenue ~$71M in Q1 2026, up 45% YoY; U.S. Amtagvi revenue ~$60M, Proleukin ~$11M.
FY 2026 revenue guidance $350-$370M; Q2 2026 guidance $86-$88M.
Lifileucel in metastatic serous endometrial cancer: 40% confirmed ORR, 100% DCR in first 5 patients; FDA expedited path planned.
Cash ~$319M, expected to fund operations into 2028; R&D expenses down 12% vs Q4 2025.
UK MAA for lifileucel withdrawn for procedural reasons, will resubmit; EMA resubmission planned for 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.